Risk factor
Very poor trading liquidity
Profitability factor
Very poor margins and returns
About
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EB
Target Price
The average target price of CLN.WA is 23 and suggests 9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Buy
Sell